Summary:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
with an Open-Label Extension to Assess the Efficacy and Safety of ITI-007
in the Treatment of Agitation in Patients with Dementia, Including
Alzheimer’s Disease
Qualified Participants Must:
• Patient is a male or female, 55 years of age or older
•
Has a clinical diagnosis of probable Alzheimers Disease
Qualified Participants May Receive:
Compensation for time and travel